SOPHIA GENETICS SA

Sophia Genetics (SOPH) Stock

Technology sector company. Here's the price, business snapshot, and what's worth knowing about Sophia Genetics in August 2026.

SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.

Stock Performance Snapshot

Strong Buy

Analyst Rating

Analysts strongly recommend buying SOPHiA GENETICS stock, predicting significant price growth ahead.

Above Average

Financial Health

SOPHiA GENETICS demonstrates solid revenue and profitability, supported by healthy cash flow and margins.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Discover More Opportunities

ADP

AUTOMATIC DATA PROCESSING INC

Provides business process outsourcing and technology services.

ACN

Accenture

Provides consulting and technology services.

ADBE

ADOBE INC

Develops software and cloud-based solutions for digital media and digital marketing.

Baskets Featuring SOPH

Clinical Trial Tech: Growth vs Competition Risks

Clinical Trial Tech: Growth vs Competition Risks

Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.

Published: 29 October 2025

Explore Basket

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.